Exelixis Has Good News About CABO
January 28, 2016
0
EXELIXIS Good News about CABO The FDA has determined that Exelixis’ (EXEL) cabozantinib New Drug Application (NDA) for advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review. The NDA will be considered officially filed 60 days from the date of the completion of the submission, or February 20, 2016. The FDA granted Priority Review to the filing and assigned a Prescription Drug User …